{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:16:12Z","timestamp":1788264972328,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.08.027","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:24Z","timestamp":1787181924000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-cancer oncolytic virotherapy through disruption of tumor cell mitochondrial dynamics"],"prefix":"10.1016","author":[{"given":"Shufeng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanpu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changbo","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-2097","authenticated-orcid":false,"given":"Hai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.027_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2026.08.027_bib2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-026-01165-8","article-title":"Cancer burden and control in China: landscape, trends and challenges","volume":"23","author":"Xia","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib3","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy","volume":"19","author":"Gujar","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2026.08.027_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccell.2025.03.010","article-title":"The discrete charm of oncolytic viruses: Toward the finish line","volume":"43","author":"Lowenstein","year":"2025","journal-title":"Cancer cell"},{"key":"10.1016\/j.ymthe.2026.08.027_bib5","first-page":"3342","article-title":"Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer","volume":"6","author":"Coukos","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.08.027_bib6","doi-asserted-by":"crossref","first-page":"20380","DOI":"10.1002\/cam4.6622","article-title":"The tumor suppressive effect and apoptotic mechanism of TRAIL gene-containing recombinant NDV in TRAIL-resistant colorectal cancer HT-29 cells and TRAIL-nonresistant HCT116 cells, with each cell bearing a mouse model","volume":"12","author":"Jung","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ymthe.2026.08.027_bib7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.08.027_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(26)00194-4","article-title":"Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial","volume":"27","author":"Tyson","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.08.027_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.08.027_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2026.08.027_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.08.027_bib14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.08.027_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103686","article-title":"Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer","volume":"84","author":"Chen","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib16","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s007050070059","article-title":"Genome replication of Newcastle disease virus: involvement of the rule-of-six","volume":"145","author":"Peeters","year":"2000","journal-title":"Arch. Virol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51465-6","article-title":"Antiviral interferons induced by Newcastle disease virus (NDV) drive a tumor-selective apoptosis","volume":"9","author":"Ginting","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.08.027_bib18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.027_bib19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrurol.2016.84","article-title":"Oncolytic virotherapy for urological cancers","volume":"13","author":"Delwar","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.14218\/JCTH.2021.00284","article-title":"Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling","volume":"10","author":"Chen","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib21","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/biology2030936","article-title":"Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host","volume":"2","author":"Fournier","year":"2013","journal-title":"Biology"},{"key":"10.1016\/j.ymthe.2026.08.027_bib22","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1128\/JVI.01183-06","article-title":"Integrity of membrane lipid rafts is necessary for the ordered assembly and release of infectious Newcastle disease virus particles","volume":"80","author":"Laliberte","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.08.027_bib24","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2026.08.027_bib25","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.annonc.2022.08.084","article-title":"Leveraging big data of immune checkpoint blockade response identifies novel potential targets","volume":"33","author":"Bareche","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012024","article-title":"PESSA: A web tool for pathway enrichment score-based survival analysis in cancer","volume":"20","author":"Yang","year":"2024","journal-title":"Plos Comput. Biol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09915","article-title":"Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma","volume":"8","author":"de Graaf","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ymthe.2026.08.027_bib28","article-title":"Newcastle disease virus NP and P proteins induce autophagy via the endoplasmic reticulum stress-related unfolded protein response","volume":"6","author":"Cheng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.08.027_bib29","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/15548627.2021.1990515","article-title":"Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells","volume":"18","author":"Gong","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.ymthe.2026.08.027_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102837","article-title":"Newcastle-disease-virus-induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells","volume":"24","author":"Kan","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2026.08.027_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.25259\/Cytojournal_39_2024","article-title":"Newcastle disease virus promotes pyroptosis in medulloblastoma cells by regulating interferon-gamma-mediated guanylate-binding protein 1 expression and activating caspase-4","volume":"21","author":"Ren","year":"2024","journal-title":"CytoJournal"},{"key":"10.1016\/j.ymthe.2026.08.027_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011981","article-title":"The HN protein of Newcastle disease virus induces cell apoptosis through the induction of lysosomal membrane permeabilization","volume":"20","author":"Chen","year":"2024","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2026.08.027_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012737","article-title":"Newcastle disease virus infection induces parthanatos in tumor cells via calcium waves","volume":"20","author":"Qu","year":"2024","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2026.08.027_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008610","article-title":"Newcastle Disease virus infection activates PI3K\/Akt\/mTOR and p38 MAPK\/Mnk1 pathways to benefit viral mRNA translation via interaction of the viral NP protein and host eIF4E","volume":"16","author":"Zhan","year":"2020","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2026.08.027_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01322-24","article-title":"Newcastle disease virus induces clathrin-mediated endocytosis to establish infection through the activation of PI3K\/AKT signaling pathway by VEGFR2","volume":"98","author":"Fan","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.08.027_bib37","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1073\/pnas.1202810109","article-title":"Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death","volume":"109","author":"Jo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.027_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2019.04.009","article-title":"Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK\/mTOR dependent autophagy activation","volume":"454","author":"Gao","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2026.08.027_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425255.2012.681376","article-title":"Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity","volume":"8","author":"Richardson","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib40","doi-asserted-by":"crossref","first-page":"31189","DOI":"10.1073\/pnas.2017152117","article-title":"Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis","volume":"117","author":"Yi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.08.027_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/toxres\/tfaa015","article-title":"Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k\/Akt inhibition","volume":"9","author":"Xu","year":"2020","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.ymthe.2026.08.027_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.biopha.2016.11.031","article-title":"Activation of Akt and JNK\/Nrf2\/NQO1 pathway contributes to the protective effect of coptisine against AAPH-induced oxidative stress","volume":"85","author":"Hu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2026.08.027_bib43","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.08.027_bib44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/mc.20628","article-title":"Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways","volume":"49","author":"Chen","year":"2010","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ymthe.2026.08.027_bib45","doi-asserted-by":"crossref","first-page":"C1172","DOI":"10.1152\/ajpcell.00504.2010","article-title":"ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling","volume":"300","author":"Winter","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib47","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1161\/STROKEAHA.111.615559","article-title":"Increased blood-brain barrier permeability and brain edema after focal cerebral ischemia induced by hyperlipidemia: role of lipid peroxidation and calpain-1\/2, matrix metalloproteinase-2\/9, and RhoA overactivation","volume":"42","author":"ElAli","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.ymthe.2026.08.027_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21470\/1678-9741-2020-0525","article-title":"RhoA\/ROCK-1 Signaling Pathway and Oxidative Stress in Coronary Artery Disease Patients","volume":"37","author":"Dokumacioglu","year":"2022","journal-title":"Braz. J. Cardiovasc. Surg."},{"key":"10.1016\/j.ymthe.2026.08.027_bib49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.freeradbiomed.2017.06.022","article-title":"ROS-dependent activation of RhoA\/Rho-kinase in pulmonary artery: Role of Src-family kinases and ARHGEF1","volume":"110","author":"MacKay","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ymthe.2026.08.027_bib50","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41388-021-02147-z","article-title":"p53-mediated AKT and mTOR inhibition requires RFX7 and DDIT4 and depends on nutrient abundance","volume":"41","author":"Coronel","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2026.08.027_bib51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5080843","article-title":"Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis","volume":"2019","author":"Su","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ymthe.2026.08.027_bib53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.ircmb.2019.11.004","article-title":"A lipid perspective on regulated cell death","volume":"351","author":"Flores-Romero","year":"2020","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib54","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1007\/s12274-021-4031-6","article-title":"Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy","volume":"15","author":"Ban","year":"2022","journal-title":"Nano Res."},{"key":"10.1016\/j.ymthe.2026.08.027_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013564","article-title":"Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma","volume":"13","author":"Yamada","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.08.027_bib56","article-title":"Oncolytic Virus-Driven Biotherapies from Bench to Bedside","volume":"19","author":"Duan","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.ymthe.2026.08.027_bib57","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/mt.2008.286","article-title":"Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses","volume":"17","author":"Zamarin","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.027_bib58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.omto.2021.01.009","article-title":"Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models","volume":"20","author":"McAusland","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2026.08.027_bib59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer cell"},{"key":"10.1016\/j.ymthe.2026.08.027_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28693","article-title":"Drug repurposing for viral cancers: A paradigm of machine learning, deep learning, and virtual screening-based approaches","volume":"95","author":"Ahmed","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ymthe.2026.08.027_bib61","doi-asserted-by":"crossref","first-page":"29870","DOI":"10.1021\/acsomega.4c03796","article-title":"Integrated ML-Based Strategy Identifies Drug Repurposing for Idiopathic Pulmonary Fibrosis","volume":"9","author":"Ahmed","year":"2024","journal-title":"ACS omega"},{"key":"10.1016\/j.ymthe.2026.08.027_bib62","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1016\/j.csbj.2023.10.038","article-title":"Network-based drug repurposing for HPV-associated cervical cancer","volume":"21","author":"Ahmed","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ymthe.2026.08.027_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trsl.2023.07.010","article-title":"Artificial intelligence-assisted repurposing of lubiprostone alleviates tubulointerstitial fibrosis","volume":"262","author":"Samantasinghar","year":"2023","journal-title":"Transl. Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:36:12Z","timestamp":1788262572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626007082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":63,"alternative-id":["S1525001626007082"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.027","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-cancer oncolytic virotherapy through disruption of tumor cell mitochondrial dynamics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}